Healthcare
Live Price
Offline$2.92
-3.63% today
Window Change
-24.87%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cabaletta Bio, Inc. (CABA) is a Healthcare stock with a market cap of $400.00M. The stock last traded around $2.92 and down 24.9% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +29.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +29.9%, free cash flow -46.3% with operating margin 0.0% and ROIC -123.8%. Stock Foundry combines CABA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CABA
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CABA Max Drawdown
-25.93%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CABA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$46.3M
+12.6% YoY
Free Cash Flow
-$35.3M
+27.8% YoY
Revenue Growth
+0.0%
EPS Growth
+29.9%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -2M | -5M | -1M | -4M | -733K |
| Operating Income | -172M | -125M | -75M | -54M | -46M |
| EBITDA | -171M | -110M | -66M | -49M | -46M |
| Net Income | -168M | -116M | -68M | -53M | -46M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 83M | 164M | 193M | 82M | 122M |
| Total Assets | 165M | 185M | 254M | 117M | 126M |
| Total Liabilities | 53M | 33M | 17M | 12M | 8M |
| Shareholder Equity | 112M | 152M | 236M | 105M | 118M |
| Total Debt | 27M | 16M | 5M | 5M | 0 |
| Net Debt | -56M | -148M | -188M | -76M | -122M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
34M
+26.5% YoY
Capital Expenditures
1M
+52.5% YoY
Free Cash Flow
35M
+27.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-121.7%
Debt / Equity
0.24x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.